1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Outcomes after flow-diversion treatment of unruptured nonsaccular intracranial aneurysms
VariablesResults of Systematic Review and Meta-AnalysisNo. of ArticlesStatistic (95% CI) (I2)
Angiographic outcomes
 Rate of successful stent deployment178/181 = 96%11(93–98) (I2 = 0%)
 Long-term aneurysm adequate occlusion rate137/168 = 85.3%12(78.2–92.4) (I2 = 42.3%)
 Long-term aneurysm complete occlusion rate128/168 = 78.8%12(72.8–84.8) (I2 = 0%)
 Long-term adequate occlusion rate (fusiform aneurysms)116/146 = 83%11(74–92) (I2 = 48%)
 Long-term adequate occlusion rate (dissecting aneurysms)33/36 = 89%4(80–98) (I2 = 0%)
 Long-term occlusion rate among anterior circulation51/61 = 87.5%6(79–95) (I2 = 0%)
 Long-term occlusion rate among posterior circulation86/107 = 83%6(71–95) (I2 = 60%)
 Long-term adequate occlusion rate (PED)118/149 = 82%8(75–90) (I2 = 25%)
 Long-term adequate occlusion rate (other devices)21/23 = 90%3(81–98) (I2 = 0%)
Treatment-related complications and clinical outcomes
 Overall treatment-related complications41/213 = 17.4%16(12.5–22.4) (I2 = 0%)
 Transient complications21/213 = 9%15(5.6–13) (I2 = 0%)
 Permanent complications20/213 = 8%15(5–12) (I2 = 0%)
 Ischemic complications37/213 = 15%15(10–20) (I2 = 0%)
 Hemorrhagic complications4/213 = 3%15(1.2–6) (I2 = 0%)
 Treatment-related complications (fusiform aneurysms)35/162 = 17%11(10–25) (I2 = 24%)
 Treatment-related complications (dissecting aneurysms)11/51 = 19%4(10–31) (I2 = 0%)
 Treatment-related complications among anterior circulation13/81 = 14%8(7–22) (I2 = 0%)
 Treatment-related complications among posterior circulation28/132 = 20%8(3–13) (I2 = 0%)
 Treatment-related complications (PED)19/110 = 15%9(9–21) (I2 = 0%)
 Treatment-related complications (other devices)3/23 = 12%3(6–24) (I2 = 0%)
 Periprocedural/early complications (within 30 days)10/213 = 2.5%15(1–4) (I2 = 0%)
 Delayed complications (after 30 days)31/213 = 12%15(7–17) (I2 = 35%)
 Premature discontinuation of AT and related ischemic events5/93 = 5%8(2–9) (I2 = 0%)
 Treatment-related mortality1/213 = 2%15(0.2–3.5) (I2 = 0%)
 Overall rate of good neurologic outcome154/187 = 87%10(79–95) (I2 = 60%)
 Occlusion of covered branches5/72 = 7%10(2–13) (I2 = 0%)
 Symptoms related to occlusion or impaired flow of covered branches3/72 = 3%10(0.5–9) (I2 = 0%)
  • Note:—AT indicates antiplatelet therapy.